Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 10⁶ cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^2,3,11 and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)

1. Bouchareychas L, et al. 2021. iScience. 24(8):102847. PubMed
2. Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed
3. Preglej T, et al. 2020. JCI Insight. 5(4):. PubMed
4. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
5. Gutiérrez-Gutiérrez ?, et al. 2021. EMBO Rep. 22:e52905. PubMed
6. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
7. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
8. Xu X, et al. 2020. J Cell Biol. 219:00:00. PubMed
9. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
10. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
11. Yu VWC, et al. 2017. Cell. 168:944. PubMed
12. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
13. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
14. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
15. Rao X, et al. 2022. Respir Res. 23:286. PubMed
16. Wang F, et al. 2021. Cell. 184(2):422-440.e17. PubMed
17. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
18. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
19. Cheng Q, et al. 2014. J Immunol. 192:3686. PubMed
20. Saunders S, et al. 2010. J Immunol. 184:2627. PubMed
21. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
22. Li Z, et al. 2021. MBio. 12:e0254221. PubMed
23. Stofkova A, et al. 2021. Int J Mol Sci. 23:. PubMed
24. Lehrke MJ, et al. 2021. Elife. 10:. PubMed
25. Rohrbeck L, et al. 2020. Immunol Cell Biol. . PubMed
26. Zhang C, et al. 2018. Cell Res. 28:323. PubMed
27. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
28. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed

Majority of thymocytes, T cell subset

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.